Topical Phenytoin in Neuralgic Pain, Peripheral Modulation of Central Sensitization: Two Case Reports

Jan M Keppel Hesselink1 and David J Kopsky2

1Institute for Neuropathic Pain, Spoorlaan 2a, 3735 MV Bosch en Duin, The Netherlands
2Institute for Neuropathic Pain, Vespuciastraat 64-III, 1056 SN, Amsterdam, The Netherlands

Abstract

We herewith describe a topical formulation of phenytoin with a clear analgesic effect in localized neuropathic pain: in post herpetic neuralgia and trigeminal neuralgia. Such topical analgesic effect for phenytoin has not yet been described in literature. We have developed various topical phenytoin formulations and identified a stable cream base in which we compounded a range of concentrations of phenytoin up to 10%. We will present two cases supporting the analgesic effect of phenytoin cream in neuralgic pain, and discuss the putative mechanism of action of phenytoin as a topical analgesic. The essence of both cases is that, apparently, it is possible to down-regulate central sensitization processes via the modulation (inhibition) of peripheral input. This hypothesis was brought forward in 2013 based on neurophysiological data, and our clinical data seem to also support this important chapter in pain treatment. Thus, topical analgesia, in our case based on phenytoin, can play an important role in multimodal therapy of chronic neuropathic pain, related to central sensitization states.

Keywords: Neuropathic pain; Phenytoin; Topical analgesic

Introduction

In 1908 phenytoin was synthesized for the first time and the introduction into the clinic as an anticonvulsant was many years later, in 1938. Although the molecule is a centenary, its mechanisms of actions are still not fully elucidated. Since the 80s of the last century the central mechanism of action of phenytoin is in general considered to be based on its blockage of the voltage gated sodium channels. The mechanism of action of phenytoin as an analgesic when administered via a topical formulation has not been explored and discussed yet. Its mechanism will be different from local anesthetics, because patients do not report the classical anesthetic effects after application, while they do report analgesic effects, with an action of onset between 3 to 30 minutes. Furthermore, there are clear differences documented between anesthetics and anticonvulsants related to biological read-outs [1]. In 2013 Baron and Dickenson published a seminal paper on the importance of peripheral modulation in chronic pain states characterized by central sensitization [2] They pointed out that both in the pathogenesis of chronic and neuropathic pain, as well as in the treatment, peripheral input is a neglected factor and presented neurophysiological evidence to illustrate that central sensitization read-outs are reduced after topical treatment with lidocaine. It is clear that this hypothesis opens a whole new chapter of the treatment of neuropathic pain. Clinical supportive data however have been absent. We will present two cases which support the hypothesis of Baron and Dickenson.

Case Descriptions

In our Institute for Neuropathic Pain (INP) we develop compounded creams for the treatment of neuropathic pain since 2011 [3-9]. In some of these cases presented, central neuropathic pain could be reduced by the application of a topical analgesic, which is quite contra-intuitive [3].

We have developed a base formulation, which is suited to deliver and combine a number of hydrophilic and lipophilic analgesics. Phenytoin is the father of all anticonvulsants, and its multipurpose profile in non-convulsive indications such as chronic pain was established in somewhat older studies. We identified that phenytoin in itself, topically administered, especially in the dose range of 5% to 10%, had good efficacy in the absence of troublesome side effects in a number of neuropathic pain states, as far as cases can support such conclusion. Topical phenytoin does not seem to create detectable plasma levels, as phenytoin formulations used in wound healing and applied in a dose of 100 to 200 mg daily on wounds did not result in measurable plasma levels [10,11]. Patients have not reported any systemic side effects during treatment with topical phenytoin 5% and subsequently with 10%.

We developed in our clinic a fast responder test, based on single blind application of either a fingertip unit placebo cream, or a fingertip unit phenytoin cream, applied on the painful region. Most patients can flawlessly identify the active cream within 10 minutes, and in cases of small fiber neuropathic pain we could document a 50% reduction of pain within this period of time. In a number of recent articles, we have presented the clinical effects of the phenytoin cream more extensively, here we especially want to embed the cases in a discussion on the mechanism of action of the cream.

Case 1: Phenytoin 5% cream for Trigeminal Neuralgia

An 86-year-old woman, suffered since years from severe trigeminal pain with burning and tingling sensations. Gamma-knife intervention, gabapentin, lidocaine 5% patch, and duloxetine did not have any effect.
Clonazepam 0.5 mg 3 times daily made life acceptable, though she scored her pain around the eye still with a 9 on the NRS. Ketamine 10% cream did reduce some of the sharp characteristics of the pain, but its effect was barely noticeable. However, ten minutes after application of phenytoin 10% cream the pain reduced from 9 to 5 on the NRS. She had to apply the cream frequently as the analgesic effect was lasting for one to several hours only. The burning and tingling sensations were reduced from 9-10 to 6-7 after applying the cream. The subjective feeling of stiffness around the mouth was reduced from 10 to 8.

Case 2: Phenytoin 10% for Post-herpetic Neuralgia

An 83-year-old man, suffering for 2 years from thoracic herpes zoster, scored his pain as 7 to 8 on the NRS, while using pregabalin 600 mg daily. Lidocaine cream, capsaicin 8% plaster, amitriptyline had no effect on his pain. Single blind treatment with 10% ketamine cream compared to phenytoin 10% cream demonstrated superiority of the phenytoin cream. The pain reduction of 50% emerged within 20 minutes after application, lasting for around 4-6 hours. Ketamine cream had only marginal effects, if any.

Mechanisms of Action

More than 17,000 articles on phenytoin can be found in PubMed. The peak number of research papers reached 477 in 1983. Since 1983 the number of papers published each year diminished, and slowly leveled out to around 300 papers each year since 2000.

Many mechanisms of action have been reported and discussed for phenytoin, in the beginning purely related to its anti-convulsive efficacy, but soon, after the first reports of gingiva hyperplasia as a side effect, also related to these effects and other emerging indications, such as wound healing. Phenytoin has been explored in many indications, and the most recent ones are breast cancer and optic neuritis [12-14].

The first study into the mechanism of action of phenytoin was published in 1937 [15]. Putman and Merritt described the effects of phenytoin in an animal model for seizures and documented that the compound could raise the threshold for electroshock induced convulsions [15]. Twenty years after its introduction, Bray hypothesized that the main mechanism of action of phenytoin related to its anticonvulsant effect was “to produce a shift from sodium from inside the brain to the extracellular space”, and to increase the concentration of serotonin in brain tissue [16]. Discussions on the mechanism of action of phenytoin thus started in the first part of last century, but these where still quite speculative and general. Among the first mechanisms proposed in the second half of last century for phenytoin as an anticonvulsant are excitable membrane stabilization, decrease in post-tetanic potentiation, augmentation of presynaptic and postsynaptic inhibitions, and depression of synaptic transmission [17-22]. Clearly, these mechanisms of action were described at the level of biological effects in various neuronal tissues and not at the level of receptors. This changed in the 70s and 80s of the last century. From that time onwards it became clear that phenytoin inhibited sodium conductance in nerves via ion channels [20]. Later, in the 80s experiments with among other synaptosome-systems supported the idea that phenytoin blocked sodium channels [23-25]. This was the beginning of the emerging insight that phenytoin could selectively block voltage-gated sodium channels.

Voltage-gated sodium channels: A key target for phenytoin

Voltage-gated sodium channels (Nav) play a key role in cellular excitability in nerves, as well as in other tissue. There is a clear consensus that these sodium channels are amongst the most important targets of phenytoin. Phenytoin stabilizes the inactivated state of the channel by effectively blocking the Na+ conductance, while preventing synchronized high frequency firing, all leading to sensitization. Phenytoin (IC50=40 μm) has 6 times stronger sodium channel binding activity compared to lidocaine (IC50=240 μm) [26]. This is especially relevant in the context of the Baron and Dickinson hypothesis of 2013, where lidocaine was documented to be able to downregulate central sensitization read-outs after topical application [2]. Data on specific effects of phenytoin, as compared to other anticonvulsants, related to the various sodium channels in various tissues are sparse or even absent [27]. Most of the voltage-gated sodium channels are expressed in parts of the central and peripheral nervous system. Anesthetics that block such channels need therefore to be administered topically or locally to avoid undesired, systemic side effects, such as with IV lidocaine. Sodium channels however, are also to be found in the skin, and especially on the keratinocytes [28]. It is here, that the inhibitory feedback from the periphery to the central nervous system, as hypothesized by Baron and Dickinson starts.

Since some years we understand there is a family of Nav and some of these are new targets for drug development. Currently we can differentiate between 9 Nav isoforms (Nav 1.1-1.9), all sharing significant homology. Moreover, the α-subunits of these channels seem to have different cellular and subcellular expression patterns which determine their different functional role, and phenytoin might play a unique role on this level. Nav 1.3, 1.7, 1.8, and 1.9 most probably are channels for nociceptive transduction. Sadly enough only fragmentary insight exists in the role and the peripheral expression of sodium channels in pain-transducing free nerve ending in the skin and on the keratinocytes [28]. The Sodium channels, Nav1.1, Nav1.6 and Nav1.8 are abundantly present at epidermal keratinocytes [29]. These sodium channel have differential patterns of distribution within the epidermis. Labeled axons within the dermis were detected for Nav1.2, Nav1.7, Nav1.8 and Nav1.9, but its immunolabeling was much less intense compared to the keratinocytes. It was suggested that these channels could possibly contribute to pain [29]. Pathological increases have been documented in keratinocyte sodium channel expression found in skin biopsies of patients suffering from neuropathic pain [29]. Stimulation of the channel leads to increasing epidermal ATP release and triggers an excessive activation of P2X receptors on primary sensory neurons. Sodium channel immunolabeling and laminar distribution are increased in the epidermis of all painful complex regional pain syndrome (CRPS) skin biopsies [29]. Specifically, painful neuropathic sites in the skin had more intense immunolabeling for Nav1.2, Nav1.3, Nav1.5, Nav1.6, Nav1.7 and Nav1.8. These findings are strongly in support of topical treatment, and the authors concluded: “Epidermal signaling pathways merit further investigation as targets for peripherally acting analgesic drugs that lack CNS side effects”[29].

Nav1.6, Nav 1.7, Nav1.8, and Nav1.9 are also reported to be present in epidermal free nerve endings [30]. Phenytoin, dose-dependently inhibited Nav1.7 in a new activator paradigm which was presented as a possible probe to develop a rapid throughput screening assay to identify Nav1.7 antagonists [31].

Phenytoin could significantly inhibit ERK1/2 phosphorylation and at anti-convulsive concentrations (50 μm), phenytoin significantly
inhibited both persistent and transient Na+ currents in the de novo resistant breast cancer cells via blocking effects on the Nav1.5 channel.

As the major drug binding site of sodium channels is not accessible from the extracellular side, drug molecules can only access it either from the membrane phase, or from the intracellular environment [32].

Phenytoin most probably, due to its lipid nature, will at least partly enter the channel via the lipid membrane compartment. Phenytoin is expected to accumulate just inside the lipid head groups where they may alter bilayer properties or interact with its target [33]. Recent work on the bacterial voltage gated sodium channel made it likely that phenytoin has two binding sites in the pore, characterized by nonspecific, hydrophobic interactions [34]. Some clinical cases in rare forms of epilepsy, where children were good responders to treatment with phenytoin, support its effect on the overactive Nav1.6 channel [35].

Phenytoin also inhibits of calcium entry through voltage dependent L-type calcium channels [36]. Especially during excited states, for instance in neuronal models stimulated with picrotoxin, y-aminobutyricacid (GABA) type A receptor (GABAA) antagonist, phenytoin has a strong effect on the suppression of the spontaneous hyper-exciting excitatory postsynaptic currents [37].

By using modeling of neuronal networks, the differentiated effects of phenytoin were shown to be determined by the complexity of the network, as well by the heterogeneity of the components in this network [38].

Based on the above discussed findings, it is clear that phenytoin has a number of targets in the family of voltage gated sodium channels, and that these channels are distributed widely in the skin, on nociceptors and keratinocytes, having close communication. Both cell types furthermore are involved in intense cross-talk related to chronic pain and inflammation [39]. These mechanistic arguments together with the hypothesis put forward in 2013 on the relevance of phenytoin was shown to be determined by the complexity of the network, as well by the heterogeneity of the components in this network [38].

Potentiation of GABA

GABA and its receptor, a ligand-gated chloride ion channel reduce neuronal excitability in neurons. GABA most probably also plays a role in the physiology of keratinocytes, and is observed within the keratinocyte [40-42]. One of the enzymes involved in the synthesis of GABA has been identified in the skin [43]. We know that GABAB receptors, are peripheral targets for analgesia with selective GABAB agonists, such as baclofen [44]. Phenytoin in the 70s was already described as having GABA-ergic effects [18]. Moreover, neurophysiological read-outs show that phenytoin influences GABAA and GABAB [45]. The responses of neurons to GABA can be potentiated by phenytoin [46-48]. The affinity of phenytoin for the GABAB receptor is in the nano molar range [49].

N-methyl-D-aspartate (NMDA) receptor antagonism

Expression of the NMDA receptor is altered in diseased skin containing tumor necrosis factor α (TNFa), and we can find this molecule in many states of chronic inflammation [50]. Increased keratinocyte proliferation and increased inflammatory mediators such as TNFa have been found in a CRPS model [51,52]. Phenytoin attenuates α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated depolarizations by the agonists AMPA and quisqualate in mM concentration range, but is not able to fully antagonize responses to NMDA at concentrations less than 100 mM. Ionotropic glutamate receptors of the NMDA receptor type are expressed on keratinocytes [53,54]. Phenytoin could effectively decrease the synaptic excitation through influencing the NMDA receptor [45]. However, given the affinities for this receptor described for the central nervous system, these receptors most probably do not play a major role in the topical analgesia induced by phenytoin [55].

Other peripheral mechanisms of action

Effects of phenytoin on peripheral nervous system read-outs have been described since nearly half a century, based on a number of different studies and models [56-59]. Treatment in sciatic nerve rat and frog models with phenytoin, even at subclinical concentrations of 5 mg/ml, caused a significant decrement in the amplitude and increment in latency of the compound action potential [1,60]. In a rabbit model of unmethylated C fiber a reduction of conduction velocity was reported after intraperitoneal dosing with phenytoin, and this lead to a decrease in post-titanic hyperpolarization [61]. Such data support a possible mode of action via peripheral nerves, and might contribute to the analgesic effects of phenytoin after application on the skin, and strengthen even more the hypothesis of Baron and Dickenson.

Influence of phenytoin on skin cells

There are many different tissues in the skin, and as we discussed elsewhere, skin offers a multitude of targets for topical analgesia: nerve endings, keratinocytes and immune competent cells. In addition to these targets all three elements are involved in intense cross-talk [62]. We will only shortly highlight some of phenytoin's impact on skin cells. The effects of phenytoin on the keratinocytes in the skin have been outlined above in the chapter of sodium channels. Here we will describe some of phenytoin's other actions on skin level. In 1939 gingiva hyperplasia was reported after phenytoin treatment [63].

The first suggestion phenytoin could play a supporting role in healing wounds was done by Shapiro in 1958, based on its accelerated epithelialization and increased connective tissue activity [64]. One year later the first results were published documenting wound healing properties of phenytoin in a controlled clinical trial [65]. The mechanism by which phenytoin improves wound healing however, is still not identified, neither is the most optimal way of delivering topical phenytoin [11].

Phenytoin is metabolized in the skin and it was pointed out that gingiva showed significant phenytoin hydroxyls [66]. Both cytochrome P450-dependent monoxygenase and epoxide hydrolase are documented in gingiva and human skin, and thus it was suggested that gingiva and skin might be important extra hepatic sites for the metabolism of phenytoin. From a number of experiments it also became clear that phenytoin has multiple direct and indirect actions on various tissues in skin and gingiva [66]. Some of these hitherto unknown mechanisms might also play a role in the anti-nociceptive effects of topical phenytoin we found in neuropathic pain.

Conclusion

Eighty years after the first clinical use of phenytoin, new indications and new mechanisms of action keep being identified. We discovered
the analgesic activity of a topical formulation of phenytoin in localized neuropathic pain, such as post-herpetic neuralgia and trigeminal neuralgia. Our cases support the hypothesis of Baron and Dickenson put forward in 2013, that in multimodal pain therapy one should also downregulate peripheral input, even in pain states with clear central sensitization. There are a multitude of targets in the skin for understanding these peripheral analgesic mechanisms of action of phenytoin in a topical formulations, such as in creams. Both keratinocytes as well as nerve endings in the skin can serve as targets for phenytoin, and both structures carry various voltage gated sodium channels. However, there may be other, hitherto unidentified targets for phenytoin in skin structures. Phenytoin, due to its lipophilic nature, seems quite attractive as a topical agent in the treatment of neuropathic pain, especially since a number of targets relevant for the treatment of neuropathic pain reside in the various components of skin, such as keratinocytes and the nerve endings of the nociceptors.

Conflict of Interest
Both authors are patent holders of two patents related to topical phenytoin formulations.

References
1. Uemura Y, Fujita T, Ohtsubo S, Hirakawa N, Sakaguchi Y, et al. (2014) Effects of various antiepileptics used to alleviate neuropathic pain on compound action potential in frog sciatic nerves: comparison with those of local anesthetics. Biomed Res Int 2014: p. 540238.
2. Baron R, Hans G, Dickenson AH (2013). Dickenson, Peripheral input and its importance for central sensitization. Ann Neurol 74: 630-636.
3. Kopsky DJ, Keppel Hesselink JM (2010). A new combination cream for the treatment of severe neuropathic pain. J Pain Symptom Manage 39: e9-e10.
4. Kopsky DJ, liebregts R, Keppel Hesselink JM (2012). Central neuropathic pain in a patient with multiple sclerosis treated successfully with topical amitriptyline. Case Rep Med 2012: 471835.
5. Kopsky DJ, Keppel Hesselink JM (2012). High doses of topical amitriptyline in neuropathic pain: two cases and literature review. Pain Pract 12: 148-53.
6. Kopsky DJ, Keppel Hesselink JM (2013). Neuropathic pain as a result of acromegaly, treated with topical baclofen cream. J Pain Symptom Manage 46: e4-5.
7. Keppel Hesselink JM, Kopsky DJ (2013). Treatment of chronic regional pain syndrome type I with palmitolethanolamide and topical ketamine cream: modulation of nonneuronal cells. J Pain Res 6: 239-245.
8. Keppel Hesselink JM, Kopsky DJ, Sajben NL (2014). Sajben, Vulvodynia and proctodynia treated with topical baclofen 5% and palmitolethanolamide. Arch Gynecol Obstet, 2014. 290: 389-393.
9. Kopsky DJ, Keppel Hesselink JM, Bhaskar A, Hariton G, Romanenko V, et al. (2015) Analogic effects of topical ketamine. Minerva Anestesiol 81: 440-449.
10. Lewis WG, Rhodes RS (1994). Systemic absorption of topical phenytoin sodium. Ann Pharmacother 28: 961.
11. Bhatta A, Prakash S (2004). Topical phenytoin for wound healing. Dermatol Online J 10: 5.
12. Nelson M, Yang M, Dowle AA, Thomas JR, Brackenbury WJ (2015). The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis. Mol Cancer14: 13.
13. Mohammed FH, Khajah MA, Yang M, Brackenbury WJ, Luqmani, et al. (2016) Blockade of voltage-gated sodium channels inhibits invasion of endocrine-resistant breast cancer cells. Int J Oncol 48: 73-83.
14. Raufopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, et al. (2016) Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15: 259-269.
15. Putnam TJ, Merritt HH (1937) Experimental Determination of the Anticonvulsant Properties of Some Phenyl Derivatives. Science 85: 525-526.
16. Bray PF (1959) Diphenylhydantoin (dilantin) after 20 years; a review with re-emphasis by treatment of 84 patients. Pediatrics 23: 151-161.
17. Carnay L, Grundfest S (1974) Excitable membrane stabilization by diphenylhydantoin and calcium. Neuropharmacology 13: 1097-1108.
18. Deisz RA, Lux HD (1977) Diphenylhydantoin prolongs postsynaptic inhibition and ionophoretic GABA action in the crayfish stretch receptor. Neurosci Lett 5: 199-203.
19. Esplin DW (1957) Effects of diphenylhydantoin on synaptic transmission in cat spinal cord and stellate ganglion. J Pharmacol Exp Ther120: 301-323.
20. Lipicky RJ, Gilbert DL, Stillman LM (1972) Diphenylhydantoin inhibition of sodium conductance in squid giant axon. Proc Natl Acad Sci USA 69: 1758-1760.
21. Yaari Y, Pincus JH, Argov Z (1976) Inhibition of synaptic transmission by diphenylhydantoin. Trans Am Neurol Assoc 101: 195-199.
22. Fronen GH, Landgren S (1963) Effect of diphenylhydantoin on single cells in the spinal trigeminal nucleus. Neurology 13: 34-37.
23. Willow M, Kuenzel EA, Catterall WA (1984) Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and syndromes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol 25: 228-234.
24. Matsuki N, Quandt FN, Ten Eick RE, Yeh JZ (1984) Characterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells. J Pharmacol Exp Ther 228: 523-530.
25. Courtney KR, Etter EF (1983) Modulated antioxidant block of sodium channels in nerve and muscle. Eur J Pharmacol 88: 1-9.
26. Wang Y, Jones PJ, Batts TW, Landry V, Patel MK, et al. (2009) Ligand-based design and synthesis of novel sodium channel blockers from a combined phenytoin-lidocaine pharmacophore. Bioorg Med Chem 17: 7064-7072.
27. Qiao X, Sun G, Clare JJ, Werkman TR, Wadman WJ (2014) Properties of human brain sodium channel alpha-subunits expressed in HEK293 cells and their modulation by carbamazepine, phenytoin and lamotrigine. Br J Pharmacol 171: 1054-1067.
28. McIntire DM, Kirkpatrick DR, Dueck NP, Kerfeld MJ, Smith TA, et al. (2016) Pain transduction: a pharmacologic perspective. Expert Rev Clin Pharmacol 9: 1069-1080.
29. Zhao P, Barr TR, Hou Q, Dib-Hajji SD, Black JA, et al. (2008) Voltage-gated sodium channel expression in rat and human epidermal keratinocytes: evidence for a role in pain. Pain 139: 90-105.
30. Persson AK, Black JA, Gasser A, Cheng X, Fischer TZ, et al. (2010) Sodium-calcium exchanger and multiple sodium channel isoforms in intra-epidermal nerve terminals. Mol Pain 6: 84.
31. Zhao F, Li X, Jin L, Zhang F, Inoue M, et al. (2016) Development of a Rapid Throughput Assay for Identification of hNav1.7 Antagonist Using Unique Efficacious Sodium Channel Agonist, Antillatoxin. Mar Drugs 14: E36.
32. Lazar A, Lenkey N, Pesti K, Fodor L, Mike A (2015). Different pH-sensitivity patterns of 30 sodium channel inhibitors suggest chemically different pools along the access pathway. Front Pharmacol 6: 210.
33. Martin LJ, Neuris R, Corry B (2014). Molecular dynamics simulation of the partitioning of benzocaine and phenytoin into a lipid bilayer. Biophys Chem 185: 98-107.
34. Martin LJ, Neuris R, Corry B (2014). Locating the route of entry and binding sites of benzocaine and phenytoin in a bacterial voltage gated sodium channel. PLoS Comput Biol 10: e1003688.
35. Boerma RS, Braun KP, van den Broek MP, van Berkestijn ME, et al. (2016) Remarkable Phenytoin Sensitivity in 4 Children with SCN8A-related Epilepsy: A Molecular Neuropharmacological Approach. Neurotherapeutics 13: 192-197.
36. Patejdl R, Leroux AC, Noack T (2015). Phenytoin inhibits contractions of rat gastrointestinal and portal vein smooth muscle by inhibiting calcium entry. Neurogastroenterol Motil 27: 1453-1465.

37. Chou MY, Lee CY, Liou HH, Pan CY (2014). Phenytoin attenuates the hyper-excitatory neurotransmission in cultured embryonic cortical neurons. Neuropsychopharmacology 83: 54-61.

38. Thomas EA, Petros S (2013). Network-specific mechanisms may explain the paradoxical effects of carbamazepine and phenytoin. Epilepsia 54: 1195-1202.

39. Pang Z, Sakamoto T, Twari V, Kim YS, Yang F, et al. (2015) Selective keratinocyte stimulation is sufficient to evoke nociception in mice. Pain 156: 656-665.

40. Schulten R, Novak B, Schmitz B, Lübbert H (2012). Comparison of the antiepileptic drugs carbamazepine and phenytoin. Exp Dermatol 13: 516-521.

41. Warskulat U, Reinen A, Grether-Beck S, Krutmann J, Häussinger D (2004). The osmolyte strategy of normal human keratinocytes in maintaining cell homeostasis. J Invest Dermatol 123: 516-521.

42. Canellakis ZN, Milstone LM, Marsh LL, Young PR, Bondy PK (1983). GABA from putrescine is bound in macromolecular form in keratinocytes. Life Sci 33: 599-603.

43. Ito, K, Tanaka K, Nishibe Y, Hasegawa J, Ueno H (2007). GABA-synthesizing enzyme, GAD67, from dermal fibroblasts: evidence for a new skin function. Biochim Biophys Acta 1770: 291-296.

44. Whitehead RA, Puil E, Res CR, Schwarz SK, Wall RA, et al. (2012). GABA(B) receptor-mediated selective peripheral analgesia by the non-proteinogenic amino acid, isovaline. Neuroscience 213: 154-160.

45. Cunningham MO, Dhillon A, Wood SJ, Jones RS (2000). Reciprocal modulation of glutamate and GABA release may underlie the anticonvulsant effect of phenytoin. Neuroscience 95: 343-351.

46. Ayala GF, Lin S, Johnston D (1977). The mechanism of action of diphenylhydantoin or invertebrate neurons. I. Effects on basic membrane properties. Brain Res 121: 245-258.

47. Nicoll RA, Wojtowicz JM (1980). The effects of pentobarbital and related compounds on frog motoneurons. Brain Res 191: 225-237.

48. Connors BW (1981). A comparison of the effects of pentobarbital and diphenylhydantoin on the GABA sensitivity and excitability of adult sensory ganglion cells. Brain Res 207: 357-369.

49. Granger P, Biton B, Faure C, Vige X, Depoortere H, et al. (1995) Immobilization contributes to exaggerated neupeptide signaling, inflammatory changes, and nociceptive sensitization after fracture in rats. J Pain 15: 1033-1045.

50. Wei T, Guo TZ, Li W, Hou S, Kingery WS, et al. (2012). Keratinocyte expression of inflammatory mediators plays a crucial role in substance P-induced acute and chronic pain. J Neuroinflammation 9: 181.

51. Nahm WK, Philpot BD, Adams MM, Badiavas EV, Zhou LH, et al. (2004). Significance of N-methyl-D-aspartate (NMDA) receptor-mediated signaling in human keratinocytes. J Cell Physiol 200: 309-317.

52. Morhenn VB, Murakami M, O'Grady T, Nordberg J, Gallo RL (2004). Characterization of the expression and function of N-methyl-D-aspartate receptor in keratinocytes. Exp Dermatol 13: 505-511.

53. Phillips I, Martin KF, Thompson KS, Heal DJ (1997). Weak blockade of AMPA receptor-mediated depolarisations in the rat cortical wedge by phenytoin but not lamotrigine or carbamazepine. Eur J Pharmacol 337: 189-195.

54. Morrell F, Bradley W, Pashne M (1958). Effects of diphenylhydantoin on peripheral nerve. Neurology 8: 140-144.

55. Brummik J, Moretti L (1966). The effect of diphenylhydantoin on nerve conduction velocity. Neurology 16: 1217-1218.

56. So EL, Penry JK (1981). Adverse effects of phenytoin on peripheral nerves and neuromuscular junction: a review. Epilepsia 22: 467-473.

57. Raya A, Gallego J, Hermenegildo C, Puertas FJ, Romero FJ, et al. (1992). Prevention of the acute neurotoxic effects of phenytoin on rat peripheral nerve by H7, an inhibitor of protein kinase C. Toxicology 75: 249-256.

58. Zafeiridou G, Spilioti M, Kagiava A, Krikonis K, Kosmidis EK, et al. (2016). Differential effects of lacosamide, phenytoin and topiramate on peripheral nerve excitability: An ex vivo electrophysiological study. Neurotoxicology 52: 57-63.

59. Julien RM, Halpern LM (1970). Stabilization of excitable membrane by chronic administration of diphenylhydantoin. J Pharmacol Exp Ther 176: 207-212.

60. Keppel Hesselink JM, Kopsky DJ (2016). Topical analgesic creams and nociception in diabetic neuropathy: towards a rationale fundament. Clin Case Rep Rev 2: 500-502.

61. Kimball OP, Horan TN (1939). The use of Dilantin in the treatment of epilepsy. Ann Intern Med 13: 787-793.

62. Shafer WG, Beatty RE, Davis WB (1958). Effect of diphenylhydantoin sodium (dilantin, epanutin). Exp Med Surg 16: 41-53.

63. Talas G, Brown RA, McGrouther DA (1999). Role of phenytoin in wound healing--a wound pharmacology perspective. Biochem Pharmacol 57: 1085-1094.